© Drug Hunter Inc. 2018-2023
Home > SAR439859
oral sel. estrogen receptor degrader (SERD)
400 mg QD, in Ph. II for ER+/HER2- BC
from MTS of ER binders, opt. for degrd./antag.
Mol. Cancer Ther., Dec. 11, 2020
Sanofi, Vitry-sur-Seine, FR / Cambridge MA
Sanofi oral selective estrogen receptor (ER) degrader (SERD)
You don’t have time to read everything, but you can’t afford to fall behind.
Drug Hunter Premium is drug discovery, distilled, so you can quickly catch up and make informed decisions based on industry examples.
Get ahead now by requesting a trial.
Molecules of the Month
Molecule of the Year